Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.23.3
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2023
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 

​

Nine Months Ended September 30, 

​

    

2023

    

2022

    

2023

    

2022

Revenue

​

​

​

​

​

​

​

​

​

​

​

​

Qbrexza

​

$

5,865

​

$

6,265

​

$

18,038

​

$

19,752

Accutane

​

​

4,882

​

​

4,121

​

​

15,109

​

​

14,228

Amzeeq

​

​

2,336

​

​

1,161

​

​

4,904

​

​

5,892

Zilxi

​

​

681

​

​

554

​

​

1,567

​

​

1,851

Targadox

​

​

929

​

​

1,168

​

​

2,386

​

​

6,558

Exelderm

​

​

764

​

​

1,001

​

​

1,813

​

​

3,018

Ximino

​

​

(199)

​

​

1,773

​

​

567

​

​

3,775

Luxamend

​

​

21

​

​

—

​

​

21

​

​

—

Collaboration revenue

​

​

182

​

​

364

​

​

546

​

​

1,518

Revenue – related party

​

 

31

​

 

48

​

 

97

​

 

118

Other revenue

​

​

19,260

​

​

73

​

​

19,519

​

 

2,629

Net revenue

​

$

34,752

​

$

16,528

​

$

64,567

​

$

59,339